WO2000029551A3 - Cells, culture methods, and their use in autologous transplantation therapy - Google Patents

Cells, culture methods, and their use in autologous transplantation therapy Download PDF

Info

Publication number
WO2000029551A3
WO2000029551A3 PCT/GB1999/003813 GB9903813W WO0029551A3 WO 2000029551 A3 WO2000029551 A3 WO 2000029551A3 GB 9903813 W GB9903813 W GB 9903813W WO 0029551 A3 WO0029551 A3 WO 0029551A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
transplantation therapy
autologous transplantation
culture methods
host organism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/003813
Other languages
French (fr)
Other versions
WO2000029551B1 (en
WO2000029551A2 (en
Inventor
Alison Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000029551(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU10680/00A priority Critical patent/AU775597B2/en
Priority to DE69930660T priority patent/DE69930660T2/en
Priority to EP99954269A priority patent/EP1131408B1/en
Priority to JP2000582535A priority patent/JP2002530293A/en
Application filed by Individual filed Critical Individual
Publication of WO2000029551A2 publication Critical patent/WO2000029551A2/en
Publication of WO2000029551A3 publication Critical patent/WO2000029551A3/en
Publication of WO2000029551B1 publication Critical patent/WO2000029551B1/en
Anticipated expiration legal-status Critical
Priority to US11/400,767 priority patent/US20060246042A1/en
Priority to CY20061100868T priority patent/CY1105439T1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)

Abstract

The present invention provides use of a host cell population obtained from a non-diseased host organism for the preparation of a cell-composition for use in subsequent autologous transplantation therapy of said host organism.
PCT/GB1999/003813 1998-11-16 1999-11-16 Cells, culture methods, and their use in autologous transplantation therapy Ceased WO2000029551A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU10680/00A AU775597B2 (en) 1998-11-16 1999-11-16 Cells, culture methods and their uses
DE69930660T DE69930660T2 (en) 1998-11-16 1999-11-16 CELLS, CULTURAL PROCEDURE, AND ITS USE IN AUTOLOGOUS TRANSPLANTATION THERAPY
EP99954269A EP1131408B1 (en) 1998-11-16 1999-11-16 Cells, culture methods, and their use in autologous transplantation therapy
JP2000582535A JP2002530293A (en) 1998-11-16 1999-11-16 Cells, culture methods and uses thereof in autologous transplantation therapy
US11/400,767 US20060246042A1 (en) 1998-11-16 2006-04-10 Cells, culture methods, and their use in autologous transplantation therapy
CY20061100868T CY1105439T1 (en) 1998-11-16 2006-06-26 CELLS, CULTURE METHODS AND THEIR USE IN AUTOLOGOUS TRANSPLANTATION THERAPY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9825096.2 1998-11-16
GB9825096A GB2343679A (en) 1998-11-16 1998-11-16 Autologous transplantation and method for making cells dormant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/400,767 Continuation US20060246042A1 (en) 1998-11-16 2006-04-10 Cells, culture methods, and their use in autologous transplantation therapy

Publications (3)

Publication Number Publication Date
WO2000029551A2 WO2000029551A2 (en) 2000-05-25
WO2000029551A3 true WO2000029551A3 (en) 2000-10-19
WO2000029551B1 WO2000029551B1 (en) 2001-01-11

Family

ID=10842531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003813 Ceased WO2000029551A2 (en) 1998-11-16 1999-11-16 Cells, culture methods, and their use in autologous transplantation therapy

Country Status (12)

Country Link
US (1) US20060246042A1 (en)
EP (1) EP1131408B1 (en)
JP (1) JP2002530293A (en)
AT (1) ATE321843T1 (en)
AU (1) AU775597B2 (en)
CY (1) CY1105439T1 (en)
DE (1) DE69930660T2 (en)
DK (1) DK1131408T3 (en)
ES (1) ES2262346T3 (en)
GB (1) GB2343679A (en)
PT (1) PT1131408E (en)
WO (1) WO2000029551A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322806D0 (en) 2003-09-30 2003-10-29 Lifeforce Group Plc Cell bank for contingent autologous leukocyte transplantation
EP1711214A1 (en) 2004-02-02 2006-10-18 Interface Multigrad Technology (IMT) Ltd. Device for directional cooling of biological matter
JP4777908B2 (en) 2004-02-02 2011-09-21 コア・ダイナミクス・リミテッド Biological materials and methods and solutions for storage of biological materials
ATE460947T1 (en) 2004-06-07 2010-04-15 Core Dynamics Ltd METHOD FOR STERILIZING BIOLOGICAL PREPARATIONS
US8037696B2 (en) 2004-08-12 2011-10-18 Core Dynamics Limited Method and apparatus for freezing or thawing of a biological material
US8198085B2 (en) 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
DE102007004855B4 (en) * 2007-01-31 2014-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Apparatus and method for deposition of biological material in a target substrate
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
EP2943206A4 (en) * 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
ES2729640T3 (en) * 2013-10-24 2019-11-05 Neuroplast Beheer B V Procedure for reducing the inflammatory activity of a stem cell transplant and its uses
CN105219709A (en) * 2015-09-23 2016-01-06 上海吉泉生物技术有限公司 Dan Caifa sets up immunocyte storehouse and application
CL2016000753A1 (en) * 2016-03-31 2017-11-10 Fund Ciencia Para La Vida Attenuation of neurodegeneration associated with parkison's disease by inhibiting the dopamine d3 receptor in t cd4 + cells.
JP6401818B2 (en) * 2016-04-27 2018-10-10 株式会社金太郎ＣｅｌｌｓＰｏｗｅｒ Method for producing activated stem cells
DE102021116694B4 (en) * 2021-06-29 2023-03-09 Promocell Gmbh Aqueous solution for cell preservation
CN114984048A (en) * 2022-06-16 2022-09-02 浙江百越生物技术有限公司 Cell therapy for preventing and treating senile tarnish

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016715A1 (en) * 1993-01-27 1994-08-04 Hemosol, Inc. Selective cell proliferation
EP0668013A2 (en) * 1994-02-22 1995-08-23 Nippon Telegraph And Telephone Corporation Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same
WO1997030157A1 (en) * 1994-02-02 1997-08-21 Incyte Pharmaceuticals, Inc. Novel human myeloid terminal differentiation response gene
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1998039427A2 (en) * 1997-03-06 1998-09-11 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
JPH04282301A (en) * 1991-03-08 1992-10-07 Kachiku Jiyuseiran Ishiyoku Gijutsu Kenkyu Kumiai Rapid freeze drying of biological sample
AU8078894A (en) * 1993-10-08 1995-05-04 Cellpro Ii Methods for collection and cryopreservation of human granulocytes
US5704889A (en) * 1995-04-14 1998-01-06 Cobe Laboratories, Inc. Spillover collection of sparse components such as mononuclear cells in a centrifuge apparatus
US5865784A (en) * 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5922597A (en) * 1995-11-14 1999-07-13 Regents Of The University Of Minnesota Ex vivo culture of stem cells
JP2002515756A (en) * 1997-01-31 2002-05-28 ヘモソル インク． Method of producing selected lymphocytes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1994016715A1 (en) * 1993-01-27 1994-08-04 Hemosol, Inc. Selective cell proliferation
WO1997030157A1 (en) * 1994-02-02 1997-08-21 Incyte Pharmaceuticals, Inc. Novel human myeloid terminal differentiation response gene
EP0668013A2 (en) * 1994-02-22 1995-08-23 Nippon Telegraph And Telephone Corporation Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same
WO1998039427A2 (en) * 1997-03-06 1998-09-11 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters

Also Published As

Publication number Publication date
GB2343679A (en) 2000-05-17
CY1105439T1 (en) 2010-04-28
DE69930660D1 (en) 2006-05-18
EP1131408A2 (en) 2001-09-12
PT1131408E (en) 2006-08-31
DE69930660T2 (en) 2007-04-05
ATE321843T1 (en) 2006-04-15
AU775597B2 (en) 2004-08-05
US20060246042A1 (en) 2006-11-02
AU1068000A (en) 2000-06-05
WO2000029551B1 (en) 2001-01-11
DK1131408T3 (en) 2006-08-07
EP1131408B1 (en) 2006-03-29
WO2000029551A2 (en) 2000-05-25
JP2002530293A (en) 2002-09-17
GB9825096D0 (en) 1999-01-13
ES2262346T3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
AU4330597A (en) Serum-free mammalian cell culture medium, and uses thereof
WO2000024365A8 (en) Treatment of skin with adenosine or adenosine analog
AU2451297A (en) Artifical chromosomes, uses thereof and methods for preparing artificial chromosomes
AU3501197A (en) Human stem cell antigens, dna coding therefor and their use
AU2003210884A1 (en) Preparations of nucleus pulposus cells and methods for their generation, identification, and use
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
AU1265197A (en) Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use
AU1201600A (en) Controlling gene expression in living cells
AU2430601A (en) Ion implantation ion source, system and method
AU5731400A (en) Methods of preparing electrochemical cells
AU1796601A (en) Methods of preparing electrochemical cells
GB9825096D0 (en) Cells,culture methods and their uses
AU6131198A (en) Isolated mammalian neural stem cells, methods of making such cells, and methods of using such cells
AU2002336930A1 (en) Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture
AU2001232184A1 (en) Cell and sector optimization system and methods
AU2002303277A1 (en) Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
AU9269898A (en) Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy
GB2379446A (en) Cells,culture methods and their uses
AU3140697A (en) The spindly gene, methods of identification and use
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
AU8419191A (en) Dna, dna constructs, cells and plants derived therefrom
ZA200200340B (en) Storage of microorganisms, cells and tissue.
CA2337088A1 (en) Methods and constructs for protein expression
WO2000004918A3 (en) Agents for the immunotherapy of tumoral diseases
WO1998003669A3 (en) Vectors for inhibiting hiv and tumor growth

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 10680

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: B1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

B Later publication of amended claims
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 582535

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09831371

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10680/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999954269

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999954269

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 10680/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999954269

Country of ref document: EP